{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-041199","form_type":"8-K","ticker":"MBIO","cik":"0001680048","company_name":"MUSTANG BIO, INC.","filed_at":"2024-03-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.089215+00:00","generated_at":"2026-06-04T05:25:28.547946+00:00","sec_items":["8.01"],"event_type":"regulatory","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Mustang Bio provides CFIUS update on facility sale to uBriGene; investigation due by May 13, 2024","bullets":["Transaction involves sale of Worcester cell processing facility and manufacturing assets to uBriGene.","CFIUS review entered a second 45-day investigation period ending May 13, 2024.","CFIUS clearance not a condition to closing but may affect timing."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-041199","json":"https://secwatch.observer/filing/0001104659-24-041199.json","markdown":"https://secwatch.observer/filing/0001104659-24-041199.md","text":"https://secwatch.observer/filing/0001104659-24-041199.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1680048/000110465924041199/0001104659-24-041199-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1680048/000110465924041199/tm2410237d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T05:25:28.547946+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}